ERYTECH Closes €70.5 Million Private Placement to US + European Investors

Boston – May 3, 2017 – Cooley advised ERYTECH Pharma on a private placement of its ordinary shares to qualified investors in the US and Europe. Total gross proceeds to ERYTECH were approximately €70.5 million.

ERYTECH, based in Lyon, France, with US headquarters in Cambridge, MA, is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s ordinary shares are listed on Euronext Paris.

Cooley advised ERYTECH on its €25 million private placement in 2015 and its €10 million private placement in 2016.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Marc Recht Partner, Boston
Div Gupta Partner, New York
Brian Leaf Partner, Reston
Courtney Thorne Associate, Boston
Stephanie Gentile Partner, New York
Francis Wheeler Partner, Colorado
Related Practices & Industries

Public Companies Capital Markets Tax